Canada gives green light to Roche's Rituxan
This article was originally published in Scrip
Executive Summary
Health Canada has approved Roche's Rituxan (rituximab) in combination with chemotherapy for previously untreated patients with chronic B-cell lymphocytic leukaemia (CLL) stages B or C.